Biodexa Pharmaceuticals Raises $3.5M Amid Cash Burn and Clinical Trial Progress — Biodexa Pharmaceuticals PLC

Event summary

Biodexa Pharmaceuticals raised $3.5M in July 2026 through a combination of a registered direct offering, warrant inducement, and PIPE offering.
The company's R&D costs increased by 75% to £2.92M in 1H26, driven by the Serenta trial and manufacturing costs for the newly in-licensed MTX240 program.
As of June 30, 2026, 92 subjects out of a planned 168 had been enrolled in the Serenta trial, with approval from Health Canada to expand the trial into Canada in June 2026.
The company's cash balance at June 30, 2026, was £3.23M, with a net loss of £1.84M for the period.

The big picture

Biodexa Pharmaceuticals is navigating a challenging financing environment while advancing its clinical trials. The company's strategic focus on gastrointestinal cancers and rare diseases positions it in a niche market with significant unmet medical needs. However, its ability to secure additional financing and achieve regulatory milestones will be critical to its long-term viability.

What we're watching

Cash Burn Dynamics: Whether Biodexa can sustain its current burn rate and secure additional financing before its cash resources run out.
Trial Execution: The pace at which Biodexa can complete enrollment in the Serenta trial and achieve key milestones.
Regulatory Headwinds: How Biodexa will navigate Nasdaq's proposed minimum market value requirement and maintain compliance with listing requirements.